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Abstract
Background
We hypothesized that heterogeneity exists within the Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) 1 spirometric category and that different subgroups could be
identified within this GOLD category.
Methods
Pre-randomization study participants from two clinical trials were symptomatic/asymptomat-
ic GOLD 1 chronic obstructive pulmonary disease (COPD) patients and healthy controls. A
hierarchical cluster analysis used pre-randomization demographics, symptom scores, lung
function, peak exercise response and daily physical activity levels to derive
population subgroups.
Results
Considerable heterogeneity existed for clinical variables among patients with GOLD 1
COPD. All parameters, except forced expiratory volume in 1 second (FEV1)/forced vital ca-
pacity (FVC), had considerable overlap between GOLD 1 COPD and controls. Three-clus-
ters were identified: cluster I (18 [15%] COPD patients; 105 [85%] controls); cluster II (45
[80%] COPD patients; 11 [20%] controls); and cluster III (22 [92%] COPD patients; 2 [8%]
controls). Apart from reduced diffusion capacity and lower baseline dyspnea index versus
controls, cluster I COPD patients had otherwise preserved lung volumes, exercise capacity
and physical activity levels. Cluster II COPD patients had a higher smoking history and
greater hyperinflation versus cluster I COPD patients. Cluster III COPD patients had re-
duced physical activity versus controls and clusters I and II COPD patients, and lower
FEV1/FVC versus clusters I and II COPD patients.
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Conclusions
The results emphasize heterogeneity within GOLD 1 COPD, supporting an individualized
therapeutic approach to patients.
Trial registration
www.clinicaltrials.gov. NCT01360788 and NCT01072396.
Introduction
According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [1] spiromet-
ric classification, mild airflow obstruction is defined by a post-bronchodilator forced expired
volume in 1 second (FEV1) to forced vital capacity (FVC) ratio at a fixed cut-off of<0.70 and
an FEV180% predicted [2]. Although this grading severity system has proved to be of value
in the assessment of chronic obstructive pulmonary disease (COPD), it is a simplistic approach,
poorly representing the complexity of COPD [3].
According to the Burden of Obstructive Lung Disease (BOLD) study [4], which used the
2006 GOLD consensus report [5], patients with mild COPD represent nearly 45% of patients
with COPD, the remainder being GOLD stage 2 to 4. Paradoxically, there is limited informa-
tion on patients with mild COPD even though they represent a large portion of patients with
COPD. While the latest GOLD statement places emphasis on a more broad assessment of the
disease [2], there is still a need to refine the GOLD classification, to avoid misclassification of
patients with mild COPD. Accordingly, phenotypes could be one promising approach to the
clinical heterogeneity of COPD [6]; potentially helping to identify a better type of approach to
use for patients with mild disease.
We took advantage of a cohort of symptomatic and asymptomatic patients with mild
COPD to explore possible heterogeneity in GOLD 1 COPD and to evaluate whether different
subtypes of patients could be identified within this GOLD category. We used cluster analysis to
divide our population into subgroups (clusters) according to the clinical parameters included
in the study. The participants were characterized in five different domains: 1) baseline charac-
teristics; 2) symptoms; 3) baseline lung function; 4) peak exercise response; and 5) levels of
physical activity (steps/day, daily energy expenditure>3 metabolic equivalents [METs], daily
time>3 METs). Since the clinical significance of this relatively new category of patients with
mild COPD has been questioned [7–9], we also included healthy control subjects in the cluster
analysis to investigate how the GOLD 1 patients would be differentiated. Based on the notion
that considerable heterogeneity exists within GOLD 2 to 4 COPD [10], we hypothesized that a
similar phenomenon would be seen within the GOLD 1 category and that different clinical
phenotypes could be identified.
Methods
Study Design and Subjects
Data for this study were obtained, pre-randomization, from a single-center study, aimed at
characterizing mild COPD and its exercise response to bronchodilation (ClinicalTrials.gov
identifier: NCT01360788) and a multicenter clinical study involving 14 investigation sites,
aimed at evaluating exercise response to bronchodilation in mild-to-moderate COPD
(NCT01072396). The protocols for the individual trials are available in S1 Protocol
Clusters in Mild COPD
PLOSONE | DOI:10.1371/journal.pone.0123626 April 23, 2015 2 / 16
which was contracted and compensated by BIPI and
Pfizer Inc for these services.
Competing Interests: The authors of this manuscript
have the following competing interests: PG declares
that he has no competing interests. RC is a
consultant for Boehringer Ingelheim, Forest and
Novartis. He has served on advisory boards for
Boehringer Ingelheim and Forest, and has received
payment for lectures including service on speakers’
bureaus from AstraZeneca, Boehringer Ingelheim,
Forest, Novartis and Pfizer. He has received payment
for development of educational presentations from
Boehringer Ingelheim. His institution has received
grants from Boehringer Ingelheim, Forest,
GlaxoSmithKline and Novartis. DS declares that he
has no competing interests. JP reports grants from
Boehringer Ingelheim, Inc., personal fees from
Boehringer Ingelheim, Inc., non-financial support from
Boehringer Ingelheim, Inc., personal fees from
Actelion, during the conduct of the study. In addition,
he has a patent US 7,628,732 and a patent US
7,927,251 issued. SP is a clinician scientist of the
Fonds de la Recherche en Santé du Québec. He has
served on advisory boards for Actelion, Eli Lilly,
GlaxoSmithKline and Pfizer and has received
payment for lectures from Actelion and Eli Lilly. His
institution has received grants from Actelion, Bayer
and GlaxoSmithKline. JM is a clinician scientist of the
Fonds de la Recherche en Santé du Québec and
declares that she has no competing interests. JB is a
recipient of a CIHR/Rx&D Collaborative Research
Program Operating Grants (# 93326) for The
Canadian Cohort of Obstructive Lung Disease
(CanCOLD). He received research funding via the
Research Institute of the McGill University Health
Centre, from AstraZeneca, Boehringer Ingelheim,
GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer
and Theratechnologies; and has served on speakers,
consultation panels and/or advisory boards for the
above listed pharmaceutical companies. DEO has
served on advisory boards for Boehringer Ingelheim,
GlaxoSmithKline, Pfizer and Roche. He has received
payment for lectures including service on speakers’
bureaus from Boehringer Ingelheim, GlaxoSmithKline
and Pfizer. His institution has received grants from
AstraZeneca, Boehringer Ingelheim,
GlaxoSmithKline, Novartis, Nycomed and Pfizer. FM
holds a GSK/CIHR Research Chair on COPD at
Université Laval. He is a consultant for Boehringer
Ingelheim. He has served on advisory boards for
Boehringer Ingelheim, GlaxoSmithKline and Pfizer
and has received payment for lectures including
service on speakers bureaus from Boehringer
Ingelheim, GlaxoSmithKline, Nycomed and Pfizer. His
institution has received grants from Boehringer
Ingelheim and GlaxoSmithKline. This does not alter
(NCT01360788) and S2 Protocol (NCT01072396). The patient characterization phase of
NCT01072396 has been published by O’Donnell et al [11].
A total of 85 patients meeting the GOLD 1 COPD spirometric classification criteria (post-
bronchodilator FEV180% predicted and FEV1/FVC<0.70) [2] and a smoking history10
pack-years were included in the study; 118 healthy subjects with normal spirometry (FEV1
>80% predicted and FEV1/FVC0.7) served as controls. All subjects must have been in a sta-
ble condition for at least 6 weeks before study enrolment. Patients with COPD treated with
short or long-acting β-adrenergic bronchodilators were asked to withdraw from their medica-
tion from 8 and 36 hours prior to the visit, respectively; similarly, short or long-acting anticho-
linergic bronchodilators were discontinued 8 hours and 2 weeks prior to the visit, respectively.
This was done in order to avoid any confounding effects on exercise testing or pulmonary func-
tion. In all groups, subjects were excluded if they presented with any medical condition, other
than COPD, likely to influence exercise testing as well as participation in physical activities of
daily life (i.e. cardiovascular, neurological, musculoskeletal, locomotor or other respiratory dis-
eases as well as β-blocker therapy).
Symptoms
The baseline dyspnea index (BDI) [12] was used to quantify the degree of dyspnea on a scale of
0 to 12, where a lower score denotes worse severity. Cough was considered present when occur-
ring daily for 3 months per year, during at least 2 consecutive years.
Pulmonary Function Testing
Standard pulmonary function tests, including spirometry, lung volumes (by plethysmography)
and diffusion capacity (DLCO) were obtained according to previously described guidelines [13]
and related to predicted normal values [14]. The FEV1/FVC ratio was compared with the lower
limit of the normal (LLN) range according to the National Health and Nutrition Examination
Survey (NHANES) III predicted values [15]. The predicted value for inspiratory capacity (IC)
was obtained by subtracting the functional residual capacity (FRC) predicted value from the
total lung capacity (TLC) predicted value. Maximum voluntary ventilation (MVV) was esti-
mated by multiplying FEV1 by 35 [16].
Exercise Testing
Peak exercise capacity was determined using a walking exercise test, either an incremental
shuttle walk test (ISWT) (NCT01360788) or an incremental treadmill exercise test
(NCT01072396).
Incremental shuttle walking test. The originally described test [17], was modified to add
three additional speed steps in order to reach symptom limitation in all participants [18]. Sub-
jects were allowed to run in order to attain maximal exercise capacity. During the ISWT, sub-
jects breathed through a facemask, connected to a portable gas exchange analyzer (Oxycon
Mobile, Viasys Healthcare, Jaeger, Germany), which measured oxygen consumption (V0O2),
carbon dioxide output (V0CO2) and minute ventilation (V0E). Dyspnea and leg fatigue Borg
scores [19] were obtained at baseline and at end of exercise; with higher scores indicating
worse severity. Finally, the locus of symptom limitation was determined by asking whether par-
ticipants stopped exercise because of dyspnea/leg fatigue/both or for another reason.
Incremental treadmill exercise test. The incremental treadmill test was performed in a
ramp-fashion adapted from the protocol established by Porszasz et al. [20], with a 10 W•min–1
and a 15 W•min–1 increase for patients with GOLD 1 COPD and control subjects, respectively.
As for the ISWT, subjects were connected to a gas exchange analyzer using a mouthpiece and a
Clusters in Mild COPD
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nose clip. Finally, the same procedure as for the ISWT was implemented for effort perception
and locus of symptom limitation.
Levels of Physical Activity
Physical activity in daily life was monitored during 7 to 14 consecutive days via a monitor (Sen-
seWear ArmBand, BodyMedia Inc., Pittsburgh, PA, USA), which was worn on the right upper
arm for at least 12 hours per day. This device produced estimates of the steps taken per day, as
well as daily time and energy expenditure associated with at least moderate intensity (>3
METs). We report the mean daily values over the period of measure.
Cluster Analysis
Hierarchical cluster analysis was used to define homogeneous groups of individuals based on
given parameters [21]. This analysis was performed usingWard’s minimum-variance method
and distances between individuals were measured in the metric of the pooled within-cluster co-
variance matrix as proposed by Art and colleagues [22]. The analysis results in groups (clusters)
of members who share strong associations, while these associations are weak between members
of different clusters [23]. Hierarchical clustering methods first assigned each individual to their
own cluster. Then the most similar pairs of clusters (in terms of the chosen distance metric) were
merged into a new cluster, so that there was one less cluster. The iteration process continued by
merging the next two similar clusters, or new clusters, until all individuals could be included in a
cluster. The parameters included in the analysis are shown in Table 1. The number of clusters
was determined by using three statistics (pseudo F statistic, pseudo t2 statistic and cubic cluster-
ing criterion), which performed best in the simulation study of Milligan and Cooper [24].
Ethics Statement
The parent clinical trials, from which data were obtained for this cluster analysis study, were
carried out in compliance with the approved protocols, the principles laid down in the
Table 1. Clinical parameters included in the analysis.
Domain Parameters
Baseline
characteristics
Age, sex, weight, height, BMI, smoking status (never/former/active), smoking
history (pack-years)
Symptoms Cough with sputum production for 3 months/year during 2 consecutive years
(yes/no)
BDI score (scale 0–12)
Lung function % predicted value: FEV1, FVC, IC, TLC, FRC, RV, DLCO
Ratio: FEV1/FVC, IC/TLC, RV/TLC
Lower limit of normal status: FEV1/FVC (over/under)
Peak exercise
response
V0O2 peak (mL•kg
-1
•min-1), V0E peak (L•min
-1), V0E peak/MVV, VT (% predicted VC),
Bf, V0E/V0O2, V0E/V0CO2, dyspnea peak (Borg score; scale 0–10), leg fatigue peak
(Borg score; scale 0–10), limiting factor (dyspnea/leg fatigue/both/other)
Levels of physical
activity
Steps per day, daily energy expenditure >3 METs (kcal), daily time >3 METs
(min)
BMI: body mass index; BDI: Baseline Dyspnea Index; FEV1: forced expiratory volume in 1 second; FVC:
forced vital capacity; IC: inspiratory capacity; TLC: total lung capacity; FRC: functional residual capacity;
RV: residual volume; DLCO: diffusion capacity; V0O2: oxygen uptake; V0E: minute ventilation; MVV: maximal
voluntary ventilation by multiplying FEV1 by 35; VT: tidal volume; VC: vital capacity; Bf: breathing
frequency; V0CO2: carbon dioxide output; METs: metabolic equivalents.
doi:10.1371/journal.pone.0123626.t001
Clusters in Mild COPD
PLOSONE | DOI:10.1371/journal.pone.0123626 April 23, 2015 4 / 16
Declaration of Helsinki version as of October 1996 and in accordance with the International
Conference on Harmonisation Tripartite Guidelines for Good Clinical Practice. Written in-
formed consent was obtained from all participants; the study protocols, informed consent and
patient information were reviewed and approved by local Institutional Review Boards/Inde-
pendent Ethics Committees. NCT01360788: Comité d’Éthique de la Recherche de I’Institut
Universitaire de Cardiologie et de Pneumologie de Quebéc (Québec, QC). NCT01072396:
Chesapeake Research Review, Inc. (Columbia, MD); The John F. Wolf, M.D. Human Subjects
Committee of the Los Angeles Biomedical Research Institute at Harbor UCLAMedical Center
(Torrance, CA); Partners Human Research Committee (Boston, MA); Western Institutional
Review Board (Olympia, WA); Springfield Committee for Research Involving Human Subjects
(Springfield, IL); Trustees of Dartmouth College, Dartmouth–Hitchcock Medical Center,
Committee for the Protection of Human Subjects (Hanover, NH); Saint Francis Hospital and
Medical Center Institutional Review Board (Hartford, CT); McGill University Health Center
Research Ethics Office (Montreal, QC); Comité d’Éthique de la Recherche de I’Institut Univer-
sitaire de Cardiologie et de Pneumologie de Quebéc (Québec, QC); Queen’s University, Health
Sciences and Affiliated Teaching Hospitals Research Ethics Board (Kingston, ON); and Centre
Hospitalier de l’Université de Montreal (CHUM) Research Ethics Committee (Montreal, QC).
Statistical Analysis
Results obtained in all patients with GOLD 1 COPD and controls were first shown as frequency
distributions and compared between the two groups using Pearson’s Chi-squared statistic tests.
Second, comparisons were made between the clusters, which were identified through the clus-
ter analysis. Quantitative variables, expressed as mean ± standard deviation (SD), were com-
pared among clusters using an analysis of variance (ANOVA) model. Following a significant
finding, Tukey’s post hoc multiple comparisons technique was used to compare each cluster
with the other clusters. Qualitative variables, expressed as percentages, were compared among
clusters using Pearson’s chi-squared statistic test. All analyses were done at the level of signifi-
cance of p<0.05.
Results
Heterogeneity in GOLD 1 COPD
The frequency distributions for pulmonary function, peak V0O2, BDI score and physical activity
are provided in Fig 1. FEV1% predicted, FEV1/FVC and DLCO % predicted were lower while
TLC, FRC and reserve volume (RV) were higher in patients with GOLD 1 COPD compared
with controls (all p<0.001). For all these variables, with the exception of FEV1/FVC ratio, a
considerable degree of overlap between GOLD 1 COPD and controls was seen. Compared with
controls, peak V0O2 was lower on average by 15% in patients with COPD, who also expressed a
lower BDI score. The number of steps per day tended to be reduced in COPD compared with
control (p = 0.09). No difference was observed for daily time spent at physical activity>3
METs between the two groups (p = 0.47).
Cluster Analysis
We obtained a three-cluster solution, which best fitted the parameters and subjects included in
the study; this decision was based on local peaks of the cubic clustering criterion and pseudo F
statistic combined with a small value of the pseudo t2 statistic and a larger value for the next
cluster fusion (Fig 2a) [24]. This was also in accordance with the dendrogram issued from the
hierarchical Ward’s clustering method (Fig 2b) [25]. Cluster I included 105 controls and 18
Clusters in Mild COPD
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Fig 1. Frequency distributions for pulmonary function, peak V0o2, BDI score and physical activity. a) forced expiratory volume in 1 second (FEV1); b)
FEV1/forced vital capacity (FVC) ratio; c) total lung capacity (TLC); d) functional residual capacity (FRC); e) residual volume (RV); f) diffusion capacity (DLCO);
g) peak oxygen uptake (V0O2 peak); h) baseline dyspnea index (BDI) score; i) number of steps per day; j) and daily time spent in physical activity >3 metabolic
equivalents (METs). GOLD: Global Initiative for Chronic Obstructive Lung Disease.
doi:10.1371/journal.pone.0123626.g001
Clusters in Mild COPD
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patients with GOLD 1 COPD, while clusters II and III were mostly composed of patients with
GOLD 1 COPD (Fig 3).
The characteristics of the patients with COPD in the three clusters, excluding the controls
from this analysis, are presented in Table 2. Patients in the three clusters had a similar body
Fig 2. Determination of the number of clusters. a) Using three statistics (the statistical value of pseudo F statistic and cubic clustering criterion are
reported on the left Y axis while the statistical value for pseudo t2 statistic is reported on the right Y axis) and b) hierarchical Ward’s clustering method.
doi:10.1371/journal.pone.0123626.g002
Clusters in Mild COPD
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mass index and sex distribution; patients in cluster III were older than those in cluster II
(p = 0.03). Smoking history was significantly higher in patients belonging to cluster II than
cluster I (p = 0.002). Prevalence of cough and dyspnea BDI scores was similar across the clus-
ters (Table 2). Pulmonary function data are provided in Table 2 and Fig 4. Except for lung vol-
umes in patients belonging to cluster I, other pulmonary function indices were impaired in
patients in the three clusters compared with control values (p<0.01; Fig 4). The three clusters
of patients with COPD had similar FEV1 (Fig 4), but FRC and RV were significantly increased
in cluster II compared with cluster I (p = 0.01 and p = 0.04, respectively). Cluster II also tended
to display a lower IC/TLC ratio compared with cluster I (0.43 ± 0.08 versus 0.48 ± 0.07;
p = 0.07). Finally, cluster III was differentiated from clusters I and II by a significantly lower
FEV1/FVC ratio (p = 0.002 and p = 0.008, respectively).
Although patients in the three clusters had similar peak V0O2, only patients in clusters II and
III showed a significantly reduced peak V0O2 compared with controls (p<0.01; Fig 5). The
number of step per day and amounts of physical activity with energy expenditure>3 METs
was significantly reduced in patients in cluster III compared with controls (p<0.01) and pa-
tients in clusters I (p<0.001) and II (p<0.001). As indicated in Table 3, patients belonging to
cluster III differed from those of cluster II on the basis of a significantly higher V0E/MVV ratio
at peak exercise (p<0.001). When compared with patients in clusters I and II, patients in Clus-
ter III had significantly higher V0E/V0O2 ratio (p = 0.005 and p = 0.05, respectively), higher re-
spiratory exchange ratio at peak exercise (p = 0.01 and p<0.001, respectively) and were mainly
limited by dyspnea (p = 0.02; Table 3).
Discussion
This study highlights heterogeneity in the clinical manifestations of GOLD 1 COPD, as defined
by the 2014 GOLD consensus report [1]. Three clusters of patients with GOLD 1 COPD could
be identified: cluster I was characterized by reduced DLCO and decreased BDI dyspnea scores
(compared with controls) with preserved lung volumes, exercise capacity and physical activity
levels; cluster II showed more prominent static hyperinflation (FRC) and gas trapping (RV) but
preserved levels of physical activity; and cluster III exhibited marked reduction in physical activ-
ity levels and higher V0E/MVV ratio, V0E/V0O2 and respiratory exchange ratio at peak exercise.
Heterogeneity in the clinical manifestations of COPD has been highlighted in patients in-
volved in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate
Endpoints) cohort [10]. The present study extends these results by showing a similar
Fig 3. Proportion of controls subjects and patients with GOLD grade 1 COPDwithin each cluster.
doi:10.1371/journal.pone.0123626.g003
Clusters in Mild COPD
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Table 2. Characteristics of patients with GOLD grade 1 COPD by cluster.
Domain/Parameters Cluster I (n = 18) Cluster II (n = 45) Cluster III (n = 22) p-value
Cluster I
versus II
Cluster I versus
III
Cluster II
versus III
Demographics
Age, years 64 ± 6 [61–66] 61 ± 8 [58–64] 66 ± 6 [63–69] 0.46 0.58 0.03
Male, n (%) 9 (50) 30 (67) 14 (64) 0.46
BMI, kg•m–2 27 ± 3 [25–28] 27 ± 4 [26–28] 27 ± 4 [25–28] 0.68 0.96 0.84
Smoking status, former/
active %
94/6 60/40 59/41 0.02
Smoking history, pack–
years
33 ± 15 [25–40] 51 ± 22 [45–58] 43 ± 15 [36–49] 0.002 0.21 0.20
Symptoms
Cough, no/yes % 61/39 42/58 45/55 0.39
BDI scale 8.5 ± 1.9 [7.6–9.4] 7.5 ± 2.1 [6.9–8.1] 8.3 ± 1.0 [7.8–8.7] 0.14 0.92 0.25
Lung function
FEV1, L 2.60 ± 0.67 [2.26–
2.93]
2.79 ± 0.69 [2.58–
3.00]
2.54 ± 0.62 [2.26–
2.81]
0.55 0.96 0.31
FEV1, % predicted 94 ± 12 [88–100] 97 ± 13 [94–101] 95 ± 10 [91–100] 0.63 0.95 0.82
FVC, L 4.00 ± 0.98 [3.51–
4.49]
4.44 ± 1.14 [4.10–
4.78]
4.30 ± 0.99 [3.86–
4.75]
0.30 0.63 0.88
FVC, % predicted 118 ± 13 [111–124] 124 ± 14 [119–128] 130 ± 17 [122–137] 0.32 0.02 0.22
FEV1/FVC, % 65 ± 5 [63–67] 63 ± 5 [62–65] 59 ± 6 [56–62] 0.54 0.002 0.008
FEV1/FVC, <LLN % 61 76 86 0.18
IC, L 3.09 ± 0.91 [2.64–
3.55]
3.03 ± 1.02 [2.72–
3.34]
2.99 ± 0.80 [2.64–
3.35]
0.96 0.94 0.99
IC, % predicted 110 ± 20 [100–120] 104 ± 21 [98–110] 109 ± 19 [100–118] 0.57 0.99 0.63
TLC, L 6.33 ± 1.16 [5.75–
6.90]
6.95 ± 1.62 [6.46–
7.44]
6.60 ± 1.22 [6.06–
7.14]
0.27 0.82 0.62
TLC, % predicted 107 ± 12 [101–113] 113 ± 15 [109–118] 111 ± 11 [106–116] 0.20 0.52 0.86
FRC, L 3.25 ± 0.45 [3.03–
3.48]
3.92 ± 0.95 [3.64–
4.22]
3.64 ± 0.83 [3.28–
4.02]
0.01 0.32 0.40
FRC, % predicted 104 ± 16 [96–112] 122 ± 25 [114–129] 114 ± 23 [104–125] 0.02 0.37 0.45
RV, L 2.24 ± 0.41 [2.05–
2.45]
2.71 ± 0.81 [2.47–
2.95]
2.48 ± 0.50 [2.26–
2.70]
0.04 0.53 0.38
RV, % predicted 102 ± 17 [93–110] 123 ± 36 [112–134] 110 ± 23 [100–120] 0.03 0.68 0.21
IC/TLC 0.48 ± 0.07 [0.45–
0.52]
0.43 ± 0.08 [0.41–
0.46]
0.45 ± 0.09 [0.41–
0.49]
0.07 0.52 0.58
RV/TLC 0.36 ± 0.05 [0.33–
0.39]
0.39 ± 0.08 [0.37–
0.42]
0.38 ± 0.07 [0.35–
0.42]
0.27 0.64 0.84
DLCO, % predicted 79 ± 15 [72–87] 76 ± 23 [69–83] 73 ± 18 [65–82] 0.86 0.64 0.85
Comorbidities
Hypertension, n (%) 8 (44) 16 (36) 6 (27) – – –
Dyslipidemia, n (%) 7 (39) 16 (36) 7 (32) – – –
Coronary heart disease, n
(%)
1 (6) 5 (11) 0 (0) – – –
Diabetes, n (%) 0 (0) 2 (4) 0 (0) – – –
Neoplasia, n (%) 2 (11) 0 (0) 0 (0) – – –
Data are mean ± SD [95% confidence interval], unless otherwise specified.
Reported p-values for the ordinal variables (distribution) refer to Chi-squared test values from the contingency analysis.
BMI: body mass index; BDI: baseline dyspnea index; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; LLN: lower limit of normal;
IC: inspiratory capacity; TLC: total lung capacity; FRC: functional residual capacity; RV: residual volume; DLCO: diffusion capacity.
doi:10.1371/journal.pone.0123626.t002
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Fig 4. Pulmonary function parameters expressed as percentage of predicted values by cluster. a)
forced expiratory volume in 1 second (FEV1); b) total lung capacity (TLC); c) functional residual volume
(FRC); d) residual volume (RV); and e) diffusion capacity (DLCO); as well as f) FEV1/forced vital capacity
(FVC) ratio by cluster of patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 1
chronic obstructive pulmonary disease. Values are mean ± SD. Dashed lines represent mean values in
control subjects. *p<0.01 versus healthy controls; †p<0.05 versus cluster I; ‡p<0.01 versus cluster I and II.
doi:10.1371/journal.pone.0123626.g004
Clusters in Mild COPD
PLOSONE | DOI:10.1371/journal.pone.0123626 April 23, 2015 10 / 16
phenomenon within the GOLD 1 COPD category. One potential implication of these findings
is that all patients within the GOLD 1 COPD category should not be considered as having the
same disease. Some of them (cluster I) may exhibit preserved functional capacity and physical
activity levels despite evidence of airflow obstruction. It could be argued that patients belonging
Fig 5. V0o2 peak relative to body weight and daily physical activity levels by cluster. a) Peak oxygen
consumption (V0O2 peak) relative to body weight; b) mean steps per day; c) mean daily energy expenditure
(EE); d) mean daily time >3 metabolic equivalents (METs); and e) baseline dyspnea index (BDI) score by
cluster of patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 1 chronic
obstructive pulmonary disease. Values are mean ± SD. Dashed lines represent mean values in control
subjects. *p<0.01 versus controls subjects; †p<0.05 versus cluster I and II.
doi:10.1371/journal.pone.0123626.g005
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to cluster I were actually healthy subjects who were misclassified based on a fixed FEV1/FVC
ratio [26]. This issue of misclassification is supported by the fact that the FEV1/FVC ratio was
>LLN in 39% of subjects. Conversely, decreased BDI dyspnea scores and reduced DLCO found
in this cluster would argue that these patients were nevertheless showing some pathophysiolog-
ical features of COPD. Clearly, the delineation between healthy smokers and mild COPD is not
necessarily perfect, illustrating that the differentiation between health and disease is likely to be
a continuum. However, by combining both healthy controls and patients with GOLD 1 COPD
in a cluster analysis we have illustrated that the majority of GOLD 1 patients (67/85, 79%)
stood out as being different from most healthy controls, which supports the notion that these
individuals exhibit clinical features of a “true” disease.
Patients with GOLD 1 COPD included in cluster II were mostly characterized by a substantial
smoking history (>50 pack-years) and, from a physiological standpoint, by FRC and RV
>120% predicted and reduced exercise capacity. Surprisingly, the levels of physical activity were
still preserved in cluster II. It is also interesting to consider that vital capacity was preserved in
these individuals despite static hyperinflation and gas trapping. This finding in patients with
mild airflow obstruction has been previously reported in cross-sectional studies and may have
important implications in terms of maintaining ventilatory capacity during exercise [27–30].
Patients with mild COPD in cluster III were mainly characterized by a lower FEV1/FVC
ratio, reduced exercise capacity and striking reduction in the level of physical activity compared
with the other clusters. Reduced physical activity level has already been reported in patients
with GOLD 1 COPD [31,32]. Our data add to the existing literature by showing that this reduc-
tion in physical activity may be occurring only in a subset of patients with GOLD 1 COPD.
Considering the strong negative prognostic implications of low physical activity levels in
COPD [33,34], our analysis may have identified a category of mild COPD that is at higher risk
of poor outcomes. Taking into account that increasing physical activity represents an
Table 3. Peak physiological response to exercise for patients with GOLD grade COPD by cluster.
Parameter Cluster I (n = 18) Cluster II (n = 45) Cluster III (n = 22) p-value
Cluster I
versus II
Cluster I
versus III
Cluster II
versus III
V0O2 peak, mL•kg
-1
•min-1 26.3 ± 6.1 [23.2–
29.3]
23.7 ± 5.5 [22.1–
25.4]
24.5 ± 4.6 [22.4–
26.5]
0.22 0.56 0.85
V0E, L•min-1 73 ± 25 [61–86] 72 ± 25 [64–80] 77 ± 19 [68–85] 0.98 0.89 0.73
V0E/MVV 80 ± 17 [72–89] 73 ± 15 [68–78] 87 ± 7 [83–90] 0.15 0.33 <0.001
VT, % predicted VC 56 ± 11 [51–62] 54 ± 9 [52–57] 61 ± 9 [58–65] 0.71 0.23 0.01
Bƒ, breaths•min-1 39 ± 8 [35–43] 37 ± 7 [35–40] 40 ± 7 [38–44] 0.74 0.71 0.19
V0E/V0O2 36 ± 5 [34–38] 38 ± 7 [36–40] 42 ± 5 [40–44] 0.34 0.005 0.05
V0E/V0CO2 33 ± 4 [31–35] 35 ± 6 [34–37] 34 ± 5 [32–37] 0.16 0.58 0.72
RER 1.11 ± 0.13 [1.04–
1.17]
1.09 ± 0.16 [1.04–
1.14]
1.23 ± 0.11 [1.18–
1.28]
0.88 0.01 <0.001
Dyspnea peak Borg score 5.7 ± 1.4 [5.1–6.5] 6.4 ± 2.5 [5.6–7.1] 6.8 ± 1.5 [6.1–7.4] 0.57 0.30 0.75
Leg fatigue peak Borg score 4.8 ± 2.4 [3.6–5.9] 5.6 ± 2.7 [4.8–6.5] 5.3 ± 2.3 [4.3–6.3] 0.44 0.79 0.86
Limiting factor dyspnea/legs/
both/other, %
28/55/17/0 24/38/38/0 59/23/18/0 0.02
Data are mean ± SD [95% confidence interval], unless otherwise specified.
Reported p-values for the ordinal variables (distribution) refer to Chi-Squared test values from the contingency analysis.
V0O2: oxygen uptake; V0E: minute ventilation; MVV: maximal voluntary ventilation by multiplying FEV1 by 35; VT: tidal volume; VC: vital capacity; Bf:
breathing frequency; V0CO2: carbon dioxide output; RER: respiratory exchange ratio.
doi:10.1371/journal.pone.0123626.t003
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important objective of pulmonary rehabilitation [35], our results support a possible role of this
intervention in mild COPD, particularly when FEV1/FVC is low. Interestingly, this profound
reduction in physical activity level seen in cluster III in comparison with the other two clusters
of patients with COPD was present despite similar peak V0O2. This dissociation between peak
exercise capacity and level of physical activity is important because it illustrates that these two
parameters are assessing different concepts and that although preserved peak exercise capacity
is permissive to physical activity, it does not guarantee an active lifestyle [36]. We do not have a
clear explanation for the reduced level of physical activity in cluster III. These patients had a
higher erosion of the ventilatory reserve at peak exercise [37] in comparison with the other
clusters and they were mostly limited by dyspnea at peak exercise. In the face of a similar V0E/
V0CO2, the higher V0E/V0O2 and respiratory exchange ratio observed at peak exercise in these pa-
tients may reflect greater metabolic acidosis, perhaps due to higher reliance of the limb muscles
on glycolytic metabolism. Although we can only speculate on this issue, it is interesting to con-
sider that evidence of limb muscle dysfunction has been reported in patients with mild COPD
[38,39]. Being more physically inactive, this subset of patients may be at a greater risk of devel-
oping limb muscle dysfunction.
In this study, we used the GOLD classification [1] to stratify our patients because of its wide
clinical application. However, we appreciate the fact that any attempt to categorize disease se-
verity based on FEV1 cut-offs is arbitrary in nature and that, in fact, COPD severity is a contin-
uum. Stratifying patients into subcategories is particularly useful when it helps in disease
prognostication or in individualizing clinical management. We acknowledge that we have not
reached this goal with the current study. The main purpose of the present cluster analysis was
to highlight heterogeneity in GOLD 1 COPD patients; an information potentially useful for fu-
ture studies in this specific patient population. Our results emphasize that the clinical manifes-
tations of COPD are heterogeneous, even within the same GOLD severity category, and that
the evaluation of a patient should not rely solely on FEV1. We appreciate that respiratory
symptoms were measured only once and that they may fluctuate over time [40]. In order to
avoid potential misclassifications for respiratory symptoms, all participants were studied in a
stable condition. Given the majority of men in our study, caution should be taken before apply-
ing the findings to women with mild COPD. One further potential limitation was that exacer-
bations were not systematically recorded in this population. Patients involved in study
NCT01360788 did not report any exacerbation in the year preceding their involvement in the
study, whereas patients involved in study NCT01072396 had to be stable for 6 weeks before the
trial. Therefore, we are confident that exacerbation was not a major issue in this population
and that this information would not have had a substantial impact on the outcomes of the clus-
ter analysis. It is acknowledged that the sample size for this study is relatively small, since larger
sample sizes are not available. However, this is the first time that such a group of patients with
GOLD 1 COPD has been thoroughly investigated, and the results should be followed up with a
larger sample size when available.
Patient data used in this study were pooled from two clinical trials. Some patients were ini-
tially identified through a lung cancer screening study, during which spirometry was per-
formed, and when they had completed their participation in the study, they were referred on
for participation in NCT01360788. Patients in NCT01072396 were recruited through respirol-
ogy clinics in order to evaluate the exercise response to bronchodilation in mild-to-moderate
COPD. The resultant patient population for our cluster analysis included a mixture of asymp-
tomatic and symptomatic patients; this is reflected in the heterogeneity that was found in this
population. How truly representative this cohort is of the entire GOLD 1 COPD population is
difficult to assess but we nevertheless believe that we covered a spectrum of the GOLD 1
COPD population.
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Conclusions
In conclusion, our study highlights heterogeneity within the GOLD grade 1 COPD category.
Three clusters of patients with mild COPD were identified: 1) patients with reduced FEV1/
FVC ratio and DLCO who otherwise behave like healthy subjects; 2) patients with signs of static
hyperinflation but preserved levels of physical activity; and 3) patients with profound reduction
in the level of physical activity also exhibiting further reduced ventilatory reserve at peak exer-
cise as well as higher dyspnea score and evidence of more profound metabolic acidosis com-
pared with the other clusters. These results support a more individualized therapeutic
approach to patients with GOLD 1 COPD, with some patients potentially only requiring smok-
ing cessation while others being potential candidates for more intense interventions, such as
bronchodilation, exercise training and physical activity promotion interventions. This hypoth-
esis and the robustness of our findings will need confirmation in additional
population samples.
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